Compare Stocks → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IINNNASDAQ:MOTSNYSE:NSPRNASDAQ:QNRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIINNInspira Technologies Oxy B.H.N.$1.90+5.6%$1.72$0.76▼$2.49$22.72M2.23285,335 shs61,301 shsMOTSMotus GI$0.07-12.5%$0.52$0.07▼$23.40$352K1.31306,078 shs59,675 shsNSPRInspireMD$1.91-8.6%$2.43$1.00▼$3.85$44.69M0.8466,966 shs21,334 shsQNRXQuoin Pharmaceuticals$0.66-7.0%$1.47$0.63▼$12.00$2.44M1.81497,977 shs3,021 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIINNInspira Technologies Oxy B.H.N.+5.56%-1.55%+9.20%+108.36%+62.39%MOTSMotus GI-7.65%-59.65%-85.44%-93.36%-99.46%NSPRInspireMD-8.61%-15.86%-19.41%-39.17%+95.86%QNRXQuoin Pharmaceuticals-7.03%-10.20%-21.43%-83.12%-88.05%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GI1.7638 of 5 stars3.55.00.00.00.60.00.6NSPRInspireMD2.0329 of 5 stars3.50.00.00.02.02.50.6QNRXQuoin Pharmaceuticals2.4859 of 5 stars3.55.00.00.02.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/AMOTSMotus GI3.00Buy$28.8841,150.00% UpsideNSPRInspireMD3.00Buy$4.85153.93% UpsideQNRXQuoin Pharmaceuticals3.00Buy$4.00506.06% UpsideCurrent Analyst RatingsLatest QNRX, NSPR, MOTS, and IINN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024QNRXQuoin PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $4.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/A$0.45 per shareN/AMOTSMotus GI$320K1.10N/AN/A$1.74 per share0.04NSPRInspireMD$6.20M7.21N/AN/A$1.83 per share1.04QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIINNInspira Technologies Oxy B.H.N.-$11.29MN/A0.00∞N/AN/A-158.18%-108.21%6/24/2024 (Estimated)MOTSMotus GI-$12.87M-$28.55N/A∞N/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)NSPRInspireMD-$19.92M-$1.08N/AN/AN/A-320.97%-55.71%-46.53%5/20/2024 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$10.24N/A∞N/AN/A-105.09%-55.69%5/13/2024 (Estimated)Latest QNRX, NSPR, MOTS, and IINN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023MOTSMotus GIN/A-$4.13-$4.13-$3.78N/A$0.06 million3/13/2024Q4 2023QNRXQuoin Pharmaceuticals-$2.37-$2.08+$0.29-$2.08N/AN/A3/6/202412/31/2023NSPRInspireMD-$0.20-$0.16+$0.04-$0.16$1.65 million$1.76 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIINNInspira Technologies Oxy B.H.N.0.102.612.61MOTSMotus GI0.461.761.69NSPRInspireMDN/A7.346.99QNRXQuoin PharmaceuticalsN/A3.153.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIINNInspira Technologies Oxy B.H.N.12.72%MOTSMotus GI20.06%NSPRInspireMD44.78%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipIINNInspira Technologies Oxy B.H.N.29.40%MOTSMotus GI1.57%NSPRInspireMD21.62%QNRXQuoin Pharmaceuticals3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIINNInspira Technologies Oxy B.H.N.3212.62 million8.91 millionNot OptionableMOTSMotus GI155.03 million4.95 millionNot OptionableNSPRInspireMD6523.40 million18.34 millionOptionableQNRXQuoin Pharmaceuticals43.69 million3.56 millionNot OptionableQNRX, NSPR, MOTS, and IINN HeadlinesSourceHeadlineQuoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 1.8% americanbankingnews.com - April 19 at 2:58 AMQuoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 16 at 7:03 AMMaxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Knowmarkets.businessinsider.com - March 15 at 4:02 PMQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 11:01 AMQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Resultsfinanznachrichten.de - March 14 at 5:29 PMQuoin Pharmaceuticals: Q4 Earnings Insightsbenzinga.com - March 14 at 12:29 PMQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Resultsglobenewswire.com - March 13 at 4:05 PMWhy Quoin Pharmaceuticals (QNRX) Shares Are Nosedivingmsn.com - March 7 at 6:55 PMQuoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETglobenewswire.com - March 7 at 4:05 PMQNRX: Potential Pool of Study Participants Expands; Financial Position Strengthsfinance.yahoo.com - March 6 at 7:49 PMQTI, RNLX and MTC among pre-market losersseekingalpha.com - March 5 at 9:46 AMWhy Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?msn.com - March 5 at 9:46 AMQuoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offeringfinance.yahoo.com - March 5 at 9:46 AMQuoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trialmarketwatch.com - March 4 at 2:31 PMQuoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003markets.businessinsider.com - March 4 at 2:31 PMWhy Quoin Pharmaceutical Stock Is Soaringmsn.com - March 4 at 2:31 PMSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndromeaccesswire.com - February 14 at 9:00 AMBuy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug Prospectsmarkets.businessinsider.com - December 15 at 8:05 AMQuoin Pharmaceuticals Ltd ADRmorningstar.com - December 13 at 6:21 PMQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndromefinanznachrichten.de - December 13 at 1:20 PMFDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome Treatmentmarkets.businessinsider.com - December 13 at 1:20 PMQNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approvalfinance.yahoo.com - November 13 at 7:18 PMQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 3:33 PMQuoin Pharmaceuticals Ltd ADR QNRXmorningstar.com - November 10 at 10:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInspira Technologies Oxy B.H.N.NASDAQ:IINNInspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.InspireMDNYSE:NSPRInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Quoin PharmaceuticalsNASDAQ:QNRXQuoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.